Molecular and Cellular Biologists H-1B salary at CRISPR Therapeutics, Inc.: $102,459 average ($86,362-$127,077 range). 89% approval rate.
With 16 H-1B filings, CRISPR Therapeutics, Inc. is an active sponsor of Molecular and Cellular Biologists positions at an average salary of $102k. The average offered salary of $102k is 15% above the prevailing wage for this occupation. Most positions are located in Massachusetts (89%), California (11%). The certification rate is 89%. 17% of these filings are for new employment.
| Total Filings | 18 |
| Approval Rate | 89% |
| Average Salary | $102,459 |
| Median Salary | $100,000 |
| 25th Percentile | $96,928 |
| 75th Percentile | $115,300 |
| Minimum Salary | $86,362 |
| Maximum Salary | $127,077 |
| Percentile | Salary |
|---|---|
| 10th | $87k |
| 25th | $97k |
| 50th (Median) | $100k |
| 75th | $115k |
| 90th | $117k |
Based on 16 salary records. Range: $86k – $127k.
100% of filings offer salaries above the prevailing wage, with an average premium of 14.7%. The average prevailing wage is $90k (based on 16 filings with prevailing wage data).
Average processing time is 18 days (median: 7 days). Fastest: 2 days, slowest: 204 days. Based on 18 filings.
17% of filings are for new positions, while 0% are for continued employment (18 filings with data).
Average contract duration: 36 months (median: 36 months), based on 18 filings.
| Education Level | Filings |
|---|---|
| Not Specified | 18 |
| State | Filings |
|---|---|
| Massachusetts | 16 |
| California | 2 |
CRISPR Therapeutics, Inc. has 18 H-1B filings for Molecular and Cellular Biologists positions in our database of DOL public records.
The average H-1B salary for Molecular and Cellular Biologists at CRISPR Therapeutics, Inc. is $102,459, with a median of $100,000. Salaries range from $86,362 to $127,077.
The H-1B approval rate for Molecular and Cellular Biologists positions at CRISPR Therapeutics, Inc. is 89% based on 18 DOL filings.
See how Molecular and Cellular Biologists salaries compare across different H-1B sponsors.